🧬 Early LDL Lowering and the CETP Inhibitor Obicetrapib for Heart Disease and Alzheimer's Prevention

👤 Michael Davidson - cardiologist, professor at the University of Chicago, CEO of NewAmsterdam Pharma (a biotech company developing cardiometabolic therapeutics)
🎤 Peter Attia - physician, longevity expert, host of The Drive podcast

📺 The Drive (Peter Attia) – 👥 1.04M subscribers
⏱ 2h 19m
🗓 14.09.26 (2d ago)
👁 19K

📝 Cardiologist and lipidologist Michael Davidson joins Peter Attia to discuss the causal link between LDL and cardiovascular disease, the '8-gram rule' of cumulative cholesterol exposure, the history of CETP inhibitor development, and the potential of a novel drug, obicetrapib, to protect against heart attacks and APOE4-driven dementia.

━━━━━━━━━━━━━━━

💡 KEY TAKEAWAYS

1️⃣ The 8-gram rule: cumulative cholesterol exposure drives the development of atherosclerosis
A person generally needs to accumulate roughly 8 grams of cholesterol over their lifetime to trigger cardiovascular events (e.g., 200 mg/dL over 40 years or 100 mg/dL over 80 years). Keeping lifelong LDL levels below 80 mg/dL virtually eliminates clinical atherosclerosis.

2️⃣ Prevention must focus on causal drivers rather than 10-year risk scores
Conventional 10-year risk assessment models ignore 30-year-olds, even though plaque begins accumulating decades before a heart attack occurs. Treatment should start as early as possible: lowering LDL is highly effective before a heart attack, moderately effective afterward, and completely ineffective in heart failure.

3️⃣ Raising HDL as an isolated therapeutic target was a flawed strategy in cardiology
Early cholesteryl ester transfer protein (CETP) inhibitors were designed to boost 'good' HDL cholesterol by 50-75%, but clinical trials showed no reduction in cardiovascular events without a simultaneous drop in LDL. Genetic studies confirmed that the cardioprotective benefits of CETP inhibition stem entirely from reducing ApoB and LDL particles.

4️⃣ Obicetrapib lowers LDL by 45-50% and small particles by 90% at a low 10 mg dose
NewAmsterdam Pharma's novel selective CETP inhibitor reduces LDL by 40-50%, Lp(a) by 50%, and small atherogenic particles by 90% at just 10 mg daily, while raising HDL by 150%. Combined with ezetimibe, it lowers LDL by up to 55% without the adverse side effects of first-generation CETP inhibitors.

5️⃣ High-dose statins offer diminishing returns and elevate diabetes risk
The dose-response curve for statins is distinctly non-linear: most of the LDL-lowering effect occurs at starting doses, whereas maximum doses (e.g., 80 mg atorvastatin) offer marginal incremental benefit while significantly increasing the risk of insulin resistance and liver enzyme elevations.

6️⃣ The brain runs an isolated lipid system where APOE4 impairs cholesterol clearance
The blood-brain barrier completely isolates brain cholesterol from circulating plasma lipids; the brain contains no ApoB particles, relying exclusively on ApoE and HDL-like particles. APOE4 carriers suffer from impaired astrocyte cholesterol efflux, causing toxic sterol accumulation that initiates amyloid-beta and tau cascades.

7️⃣ Obicetrapib significantly reduces Alzheimer's biomarkers (such as p-tau217) in APOE4 carriers
In the BROADWAY trial, obicetrapib led to a >20% reduction in p-tau217 and other neurodegenerative biomarkers (p-tau181, GFAP, NfL) in homozygous APOE4/4 carriers. The drug appears to stimulate the clearance of toxic 24- and 27-hydroxycholesterols across the blood-brain barrier via elevated HDL.